TESARO (TSRO) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to TESARO (TSRO) Misses Q3 EPS by 14c
October 29, 2015 4:06 PM EDT
VARUBI (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November
VARUBI added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus
Patient treatment continues in the Phase 3 NOVA trial of niraparib; based upon the observed event rate, top-line data is now anticipated to become available in Q2 2016
Clinical trials for anti-PD-1 and anti-TIM-3 antibody candidates planned to initiate in 1H 2016
Cash and cash equivalents totaled $302.5 million as of September 30, 2015
WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) --... More
October 29, 2015 4:06 PM EDT
VARUBI (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November
VARUBI added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus
Patient treatment continues in the Phase 3 NOVA trial of niraparib; based upon the observed event rate, top-line data is now anticipated to become available in Q2 2016
Clinical trials for anti-PD-1 and anti-TIM-3 antibody candidates planned to initiate in 1H 2016
Cash and cash equivalents totaled $302.5 million as of September 30, 2015
WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) --... More
